Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:GYRENASDAQ:MLYSNASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.08-2.3%$8.02$5.11▼$10.67$1.09B1.161.33 million shs2.01 million shsGYREGyre Therapeutics$8.68-22.6%$9.00$6.11▼$19.00$813.82M1.9105,046 shs2.11 million shsMLYSMineralys Therapeutics$15.96-2.2%$14.49$8.24▼$18.38$1.04B-0.3487,363 shs927,902 shsNGNENeurogene$17.28-4.2%$13.62$6.88▼$74.49$246.45M1.56243,032 shs110,750 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-2.30%-1.34%-0.12%+1.96%+46.11%GYREGyre Therapeutics-22.57%-23.52%-5.55%-24.78%-35.89%MLYSMineralys Therapeutics-2.21%+3.97%+17.96%+66.95%+27.48%NGNENeurogene-4.21%-3.95%+11.92%-0.46%-46.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.6373 of 5 stars3.51.00.00.03.30.81.9GYREGyre Therapeutics0.3791 of 5 stars0.02.00.00.02.41.70.0MLYSMineralys Therapeutics2.9062 of 5 stars3.51.00.00.04.05.00.0NGNENeurogene2.3514 of 5 stars4.40.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5042.33% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AMLYSMineralys Therapeutics 3.00Buy$38.00138.10% UpsideNGNENeurogene 2.71Moderate Buy$44.60158.10% UpsideCurrent Analyst Ratings BreakdownLatest NGNE, AUPH, GYRE, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.005/16/2025NGNENeurogeneBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$38.00 ➝ $24.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/13/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.004/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.004/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.41N/AN/A$2.63 per share3.07GYREGyre Therapeutics$100.64M8.09$0.17 per share50.49$0.18 per share48.22MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANGNENeurogene$925K266.43N/AN/A$14.51 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.43N/A-10.23%-4.41%-3.07%8/7/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.02434.00∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)NGNENeurogene-$36.32M-$4.35N/AN/AN/AN/A-32.81%-27.96%8/8/2025 (Estimated)Latest NGNE, AUPH, GYRE, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11GYREGyre TherapeuticsN/A3.723.29MLYSMineralys TherapeuticsN/A14.0214.02NGNENeurogeneN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%GYREGyre Therapeutics23.99%MLYSMineralys Therapeutics84.46%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%GYREGyre Therapeutics19.52%MLYSMineralys Therapeutics25.56%NGNENeurogene9.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataMLYSMineralys Therapeutics2865.18 million33.27 millionOptionableNGNENeurogene9014.26 million13.38 millionOptionableNGNE, AUPH, GYRE, and MLYS HeadlinesRecent News About These CompaniesDeutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE)May 23 at 3:33 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Price Expected to Rise, BMO Capital Markets Analyst SaysMay 23 at 2:29 AM | americanbankingnews.com80,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Vestal Point Capital LPMay 21 at 8:14 AM | marketbeat.comRaiffeisen Bank International AG Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)May 20, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Invests $322,000 in Neurogene Inc. (NASDAQ:NGNE)May 20, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Rating Lowered by Baird R WMay 19, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Receives $46.20 Average Price Target from BrokeragesMay 19, 2025 | americanbankingnews.comRTW Investments LP Purchases 215,000 Shares of Neurogene Inc. (NASDAQ:NGNE)May 18, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Cut to "Neutral" at Robert W. BairdMay 18, 2025 | americanbankingnews.comNeurogene (NASDAQ:NGNE) Rating Lowered to "Hold" at Baird R WMay 18, 2025 | americanbankingnews.comBaird Downgrades Neurogene (NGNE)May 16, 2025 | msn.comNeurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAVMay 16, 2025 | finance.yahoo.comStuart Cobb Sells 6,797 Shares of Neurogene Inc. (NASDAQ:NGNE) StockMay 16, 2025 | insidertrades.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $748,000 Position in Neurogene Inc. (NASDAQ:NGNE)May 16, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by AnalystsMay 16, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 23,477 Shares of Neurogene Inc. (NASDAQ:NGNE)May 16, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Neurogene Q2 Earnings?May 16, 2025 | americanbankingnews.comNeurogene (NASDAQ:NGNE) Given New $45.00 Price Target at HC WainwrightMay 15, 2025 | marketbeat.comOctagon Capital Advisors LP Increases Stake in Neurogene Inc. (NASDAQ:NGNE)May 15, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 69,422 Shares of Neurogene Inc. (NASDAQ:NGNE)May 13, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNGNE, AUPH, GYRE, and MLYS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.08 -0.19 (-2.30%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.12 +0.04 (+0.56%) As of 05/23/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Gyre Therapeutics NASDAQ:GYRE$8.68 -2.53 (-22.57%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.98 +0.30 (+3.50%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Mineralys Therapeutics NASDAQ:MLYS$15.96 -0.36 (-2.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$15.97 +0.01 (+0.06%) As of 05/23/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Neurogene NASDAQ:NGNE$17.28 -0.76 (-4.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.35 +1.07 (+6.19%) As of 05/23/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
